FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs Post author:Sam Post published:February 14, 2018 Post category:Drug Industry Daily The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily You Might Also Like Focus Label Design on Preventing Medication Errors, FDA Final Guidance Tells Drugmakers May 18, 2022 Senate vs. House Cures Legislation April 7, 2016 Alex Azar Confirmed by Senate as Next Secretary of HHS January 24, 2018